Used in neuroscience and Alzheimer’s disease research to quantify levels of amyloid beta 1-42 peptide in biological samples such as cerebrospinal fluid, plasma, and cell culture supernatants. Enables researchers to monitor Aβ1-42 accumulation, a key hallmark of Alzheimer’s pathology, in preclinical studies and drug development. Widely applied in evaluating the efficacy of therapeutic agents targeting amyloid plaque formation. Supports biomarker validation and helps assess changes in Aβ metabolism under experimental conditions. Suitable for high-throughput screening and longitudinal studies in animal models and human samples.